Atanasio
Pandiella Alonso
Publicaciones (267) Publicaciones de Atanasio Pandiella Alonso
2024
-
ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression
International Journal of Molecular Sciences, Vol. 25, Núm. 6
-
Synergistic effects of medicinal plants in combination with spices from algeria: Anticancer, antiangiogenic activities, and embrytoxicity studies
Journal of Ethnopharmacology, Vol. 330
-
T-reg transcriptomic signatures identify response to check-point inhibitors
Scientific Reports, Vol. 14, Núm. 1
-
Trastuzumab deruxtecan in breast cancer
Critical Reviews in Oncology/Hematology, Vol. 198
2023
-
An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer
Journal of experimental & clinical cancer research : CR, Vol. 42, Núm. 1, pp. 200
-
An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs
Cancer Letters, Vol. 554
-
Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer
International Journal of Biological Sciences, Vol. 19, Núm. 6, pp. 1731-1747
-
Considerations for the clinical development of immuno-oncology agents in cancer
Frontiers in immunology, Vol. 14, pp. 1229575
-
Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications
Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257
2022
-
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
International Journal of Molecular Sciences, Vol. 23, Núm. 10
-
ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology
Cancers, Vol. 14, Núm. 14
-
Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
Cancers, Vol. 14, Núm. 18
-
Genomic mapping of copy number variations influencing immune response in breast cancer
Frontiers in Oncology, Vol. 12
-
HER3 in cancer: from the bench to the bedside
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
-
Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma
Biomolecules, Vol. 12, Núm. 11
-
Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
Cancer Research, Vol. 82, Núm. 3, pp. 447-457
-
Novel adcs and strategies to overcome resistance to anti-her2 adcs
Cancers, Vol. 14, Núm. 1
-
Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis
Therapeutic Advances in Medical Oncology, Vol. 14
-
Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
-
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer
Cancer research, Vol. 82, Núm. 24, pp. 4670-4679